LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

I'll believe it when I see it !

I'll continue to hold but it's very tedious waiting around for the "good news"

I've been hanging around for ages on this one, and in the end sold as I got bored. However, today's Press Roundup has this from The Times: "Word of a tie-up between Provexis and Coca-Cola".

I think it's time to buy some again, while it's still quiet out there.

Yes, this from the Times this am... it all sounds rather laboured and drawn out and is based on evaluations at this stage..but... it's better than nothing !

AIM-listed Provexis, the developer of functional foods, held steady at 4.125p, despite word of a tie-up with Coca-Cola. The company is expected to confirm that the Atlanta-based soft drinks giant is evaluating the potential use of Fruitflow, Provexiss patented tomato extract, which it claims helps to thin the blood. Unilever is currently assessing the use of Fruitflow in dairy products.

Thanks Skyhigh - I'd not seen the details. I'm sure we'll get there eventually - have bought some this morning but didn't have a lot of spare cash as it's tied up elsewhere, waiting for profits...

From "Shares" magazine today:-

Provexis bears fruit
PXS
Published date:Thursday, October 11, 2007
Last month we reported that Provexis (PXS:AIM) was in discussions with both Coca-Cola (KO:NYSE) and PepsiCo (PEP:NYSE) about the possibility of licensing its Fruitflow technology to the drinks makers (Shares 6 September). As we go to press we understand that an announcement is imminent, probably this week.

The groups technology is designed to reduce the risk of heart disease and it is already being used under licence by Unilver (ULVR). Acceptance by one of the US drinks giants will certainly act as a further fillip for the shares, which have already risen 14% in the last month to 4.1p. In the longer term the Fruitflow technology could have further applications such as lowering the chances of deep-vein thrombosis (DVT), which would again be a significant market.

Shares says: At last the patience of shareholder is being rewarded. JM

SPECULATIVE BUY

missed 'last months report' entirely, did anyone actually see it/read it?

no move on price today seems odd, given the Times report and this article......

outlook123 - 08 Sep 2007 17:18 - 31 of 41

Chat on iii board suggests that an announcement is due by the end of this month.

Also, tipped in "Shares" magazine this week:-

http://www.sharesmagazine.com/node/1227

Thanks for that info in 40 above, Outlook123 . Can't be long now!

RNS today:
Provexis PLC
14 November 2007

Provexis and Unilever renew Fruitflow(R) Exclusivity Agreement
Provexis, developer of scientifically-proven functional food, dietary supplement
and medical food technologies, announces that it has progressed its exclusivity
agreement with Unilever plc on to look specifically at how Provexis might
develop a new format of its patented Fruitflow(R) heart-health technology for
potential application in Unilever's spread product portfolio.

Fruitflow(R) is a patented natural extract from tomato which has been shown in
human trials to reduce the propensity for aberrant blood clotting, typically
associated with cardiovascular disease, which can lead to heart attack or
stroke. Unilever has substantial global brands in the heart-health market,
primarily its Flora/Becel spreads and drinking yoghurts, which have sales in
excess of 1bn.

The partners have successfully developed a pilot-scale version of the new
concentrated format over the past year, which subsequently showed positive
results in a recent human trial. Under the terms of new agreement, which extends
for 12 months, Provexis will now further develop this new technology to deliver
a product suitable for potential incorporation into vegetable-oil based fat
spreads. Unilever will transfer certain manufacturing assets to Provexis to
facilitate this phase of the project.

There are four sectors in which Provexis is seeking major partnerships, namely,
food and dairy, beverages, products for deep vein thrombosis, and dietary
supplements and medical products.

Commenting on the renewal of the collaboration agreement, Stephen Moon, CEO of
Provexis, said: 'We are pleased with the progress made over the last year and
are now focusing on delivering this important new format in a product suitable
for Unilever's spread range.'

http://www.foodnavigator.com/news/ng.asp?n=81375-unilever-provexis-fruitflow-spreads

Interesting article - many thanks for the link, Outlook.

Provexis PLC
15 November 2007

For release at 07.00 16 November 2007


PROVEXIS plc
('Provexis' or the 'Company')

EXCLUSIVE FRUITFLOW(R) TECHNOLOGY ASSESSMENT AGREEMENT WITH THE COCA-COLA
COMPANY

Provexis plc (PXS.L), which discovers, develops and licenses
scientifically-proven functional food, medical food and dietary supplement
technologies, announces the signing of a 12 month exclusive technology
assessment agreement for its patented Fruitflow(R) anti-thrombotic technology
with The Coca-Cola Company.

The exclusivity agreement covers all beverages, with the exception of
mini-drinks. During the assessment period both parties will carry out a
programme of work including consumer testing, commercial assessment and
finalising regulatory approval in a range of territories. Subject to positive
results in these areas, the parties intend to proceed to a licensing agreement
during the period of exclusivity.

There are four sectors in which Provexis is seeking major partnerships, namely,
food and dairy, beverages, products for deep vein thrombosis, and dietary
supplements and medical products. The Company has an existing collaboration
agreement with Unilever for certain formats within the food and dairy sectors.

Oh wow!!! This is one of the things we thought was going. Great news!

Toya: feel free to join-in on the ADVFN board, which is quite lively.

I'll have a read of that - thanks. I'd put PXS forward on the list here for '10-baggers'. If these assessments work through to production, then I think we could well get there.

I agree - if they get through the 'cash burn' stage to receiving actual revenue from Coke and / or Unilever then they could easily be a 10-bagger IMHO.

.

Cool! it's all coming on nicely.....onwards and upwards! might top up on any sp weakness in the coming weeks while waiting for more news.

Can't be bad....2 bits of good news in one day..!....NPE looking good also!

This is bloody good news the sp should be way up today!!!!!! come on

From AFX NEwsfeed today:

Provexis H1 pretax loss narrows; sees continued progress in rest of year

AFX LONDON (Thomson Financial) - Provexis PLC narrowed its first-half pretax loss and said it expects the positive trend to continue for the remainder of the year.The maker of nutrition products posted pretax loss of 661,221 stg compared with 758,148 stg a year ago. Adjusted loss before interest, share compensation expense and tax of narrowed to 753,000 stg versus 1.4 mln stg a year earlier.Revenue fell to 60,936 stg compared with 66,653 stg a year earlier.TFN.newsdesk@thomson.com